NTMT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Venglustat (SCHEMBL12615329)	1.00	20/20
Venglustat (SCHEMBL12615333)	1.00	20/20
SCHEMBL18309554	1.00	20/20
SCHEMBL19407265	1.00	20/20
Venglustat (SCHEMBL19844439)	1.00	20/20
SCHEMBL15579449	0.81	20/20
SCHEMBL19837241	0.80	20/20
SCHEMBL12615324	0.71	20/20
SCHEMBL12615326	0.71	20/20
SCHEMBL12613996	0.67	20/20
SCHEMBL18993502	0.65	20/20
SCHEMBL12614566	0.64	20/20
SCHEMBL12614569	0.64	20/20
SCHEMBL18993552	0.63	20/20
SCHEMBL16007827	0.59	20/20
SCHEMBL16007828	0.59	20/20
SCHEMBL19837255	0.58	20/20
Hydrochloric Acid (SCHEMBL17504473)	0.58	20/20
SCHEMBL15578272	0.58	20/20
SCHEMBL12614770	0.58	20/20

Clinical trials — most relevant to NTMT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients	PHASE4	NOT_YET_RECRUITING
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)	PHASE2	NOT_YET_RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia	PHASE1	COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Human Requirements for the Nutrient Choline	nan	COMPLETED
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	nan	COMPLETED
Development and Validation of an Online Neurobehavioral Evaluation Tool for PTEN Patients	nan	COMPLETED
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD.	nan	UNKNOWN
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Natural History Study for Patients With Nemaline Myopathy in Spain	nan	RECRUITING
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study	nan	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a NTMT1 binder may also engage these)

Protein	Name	Similarity
D2H163	—	1.000	D2H163 →
Q5BJX0	—	0.997	Q5BJX0 →
Q2T9N3	—	0.995	Q2T9N3 →
Q8R2U4	—	0.995	Q8R2U4 →
Q6NWX7	—	0.995	Q6NWX7 →
Q4KLE6	—	0.993	Q4KLE6 →
B1H2P7	—	0.992	B1H2P7 →
Q4KL94	—	0.988	Q4KL94 →
O13748	—	0.974	O13748 →
Q5M8E6	—	0.974	Q5M8E6 →
Q504A5	—	0.973	Q504A5 →
Q9VIK9	—	0.973	Q9VIK9 →
Q07G10	—	0.973	Q07G10 →
Q9UIC8	—	0.971	Q9UIC8 →
F4ZGF2	—	0.971	F4ZGF2 →
Q9N4D9	—	0.970	Q9N4D9 →
Q9DCS2	—	0.970	Q9DCS2 →
Q6NTR1	—	0.969	Q6NTR1 →
P38340	—	0.969	P38340 →
Q6AXU8	—	0.969	Q6AXU8 →
A8WVR2	—	0.968	A8WVR2 →
Q5ZIB9	—	0.968	Q5ZIB9 →
Q8BVH9	—	0.968	Q8BVH9 →
PRMT5	Protein arginine N-methyltransferase 5	0.968	landscape →
P17571	—	0.967	P17571 →
A8KBL7	—	0.967	A8KBL7 →
Q7ZW24	—	0.967	Q7ZW24 →
Q6NUA1	—	0.967	Q6NUA1 →
Q9URX7	—	0.967	Q9URX7 →
Q8R3P0	—	0.967	Q8R3P0 →